Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Liabilities and Shareholders Equity (2022 - 2026)

HeartSciences (HSCS) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 22.9% year-over-year to $6.0 million, compared with a TTM value of $22.4 million through Oct 2025, down 38.36%, and an annual FY2025 reading of $4.2 million, down 55.56% over the prior year.
  • Liabilities and Shareholders Equity was $6.0 million for Q4 2025 at HeartSciences, down from $6.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $10.8 million in Q1 2024 and bottomed at $2.1 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 4 years is $5.5 million, with a median of $5.6 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 228.38% in 2024, then crashed 55.56% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $4.8 million in 2022, then plummeted by 50.36% to $2.4 million in 2023, then surged by 228.38% to $7.8 million in 2024, then decreased by 22.9% to $6.0 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for HSCS at $6.0 million in Q4 2025, $6.4 million in Q3 2025, and $4.2 million in Q2 2025.